surmount tirzepatide trials SURMOUNT-5: shows superior weight loss over semaglutide SURMOUNT-5 Trial: Tirzepatide vs Semaglutide

Recommended Dosage : 2-3 vials every 3 days until desired effect is achieved

propensity-matched 118,993 GLP-1 RA users to 118,993 non-users in the TriNetX network and found a modest but statistically robust 2123% higher hazard of new-onset hypersomnolence at 1 and 5 years

With a 6-day half-life, 4 half-lives = 24 days (roughly 3.5 weeks) and 5 half-lives = 30 days (roughly 4.5 weeks)

In addition to conducting regular medication reconciliation to identify what prescription medications, non-prescription medications, and supplements a patient is taking, take steps to build trust and rapport

Renewing the skin helps remove dead skin and promotes new skin cells to rise to the surface

Study 6: Cardinale 2017, safety concerns Citation: Cardinale T., Brennan K., Henry G.E